Novel approaches in the management of chronic HBV infection

Frontiers in Viral Hepatitis

Volumn , Issue , 2003, Pages 225-243

  Bartholomeusz, Angeline ^a   Furman, Phillip ^b   Locarnini, Stephen ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b Division of Organic Chemistry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27244446510     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044450986-4/50071-0     Document Type: Chapter

References (94)

1. Aguesse S, Borel C, Chevalier M, Liu S, Chu C, Cheng Y, Trepo C, Zoulim F Inhibitory effect of 2'-fluoro-5-methyl?-L-arabinosyluracil (L-FMAU), a novel L-nucleoside analog, on duck hepatitis B virus replication. Hepatology 1996, 24:A372.
2. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27:1670-1677.
3. Angus P, Richards M, Bowden S, Ireton J, Sinclair R, Jones B, Locarnini S Combination chemotherapy controls severe post-liver transplant recurrence of hepatitis B virus infection. J. Gastroenterology and Hepatology 1993, 8:353-357.
4. Aoki-Sei S, O'Brien MC, Ford H, Fujii H, Gilbert DA, Cooney DA, Johns DG, Broder S, Mitsuya H In vitro inhibition of hepatitis B virus replication by 2', 3'-dideoxyguanosine, 2', 3'-dideoxy-inosine, and 3'-azido-2', 3'-dideoxythymidine in 2.2.15 (PR) cells. J Infect Dis 1991, 164:843-851.
5. Aye T, Bartholomeusz A, Shaw T, Breschkin A, Gronen L, Bowden D, McMillan Jea Hepatitis B virus polymerase mutations during famciclovir therapy in patients following liver transplantation. Hepatology 1996, 24:285A.
6. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, Locarnini S Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997, 26:1148-1153.
7. Balzarini J, Hao Z, Herdewijn P, Johns D, De Clercq E Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci USA 1991, 88:1499-1503.
8. Bartholomeusz A, Groenen L, Locarnini SA Clinical experience with famciclovir against Hepatitis B virus and development of resistance. Intervirology 1998, 40:337-342.
9. Bartholomew M, Jansen R, Jeffers L, Reddy K, Johnson L, Bunzendhl H, Condreay L, Tzakis A, Schiff E, Brown N Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997, 349:20-22.
10. Blum HE Variants of hepatitis B, C and D viruses: molecular biology and clinical significance. Digestion 1995, 56:85-95.
11. Bock T, Torresi J, Tillmann H, Locarnini S, Manns M, Trautwein C Replication and fitness of hepatitis B virus polymerase mutants after antiviral treatment following liver transplantation. Hepatology 1999, 30:79A.
12. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Villari D, de Franchis R, Santantonio T, Brancatelli S, Colucci G, Raimondo G Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatology 2000, 31:507-512.
13. Calio R, Villani N, Balestra E, Sesa F, Holy A, Balzarini J, De Clercq E, Perno CF, Del Gobbo V Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Research 1994, 23:77-89.
14. Cane PA, Mutimer D, Ratcliffe D, Cook P, Beards G, Elias E, Pillay D Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. ntivir Ther 1999, 4:7-14.
15. Chang C, Doong S, Zhou J, Beach J, Jeong L, Chu C, Tsai C, Cheng Y, Liotta D, Schinazi R Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2', 3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. Biol Chem 1992, 267:13938-13942.
16. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild-type after cessation of therapy. Hepatology 1998, 27:1711-1716.
17. Chin R, Torresi J, Earnest-Silveira L, Bock T, Manns M, Trautwein C, Furman P, Cleary D, Locarnini S Two novel antiviral agents, DAPD and L-FMAU, which are active against wild-type and lamivudineresistant HBV. Hepatology 1999, 30:421A.
18. Chisari F, Ferrari C Hepatitis B virus immunopathogenesis. Ann Rev Immunol 1995, 13:29-60.
19. Chu CK, Boudinot FD, Peek SF, Hong JH, Choi Y, Korba BE, Gerin JL, Cote PJ, Tennant BC, Cheng Y-C Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Therapies for Viral Hepatitis 1998, 303-312. International Medical Press, London. R.F. Schinazi, J.-P. Sommadossi, H.C. Thomas (Eds.).
20. Chu CK, Ma T, Shanmuganathan K, Wang C, Xiang Y, Pai SB, Yao GQ, Sommadossi JP, Cheng YC Use of 2'-Fluoro-5-Methyl-b-L-Arabinofuranosyluracil as a Novel Antiviral Agent for Hepatitis B Virus and Epstein-Barr Virus. Antimicrobial Agents and Chemotherapy 1995, 39:979-981.
21. Colgrove R, Japour A A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. Antiviral Res 1999, 41:45-56.
22. Colledge D, Locarnini S, Shaw T Synergistic Inhibition of Hepadanaviral Replication by Lamivudine in Combination With Penciclovir In Vitro. Hepatology 1997, 26:216-225.
23. Corey L, Holmes KK Therapy for human immunodeficiency virus infection-what have we learned?. N Engl J Med 1996, 335:1142-1144.
24. Cornelissen M, van den Burg R, Zorgdrager F, Lukashov V, Goudsmit J Pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J Virol 1997, 71:6348-6358.
25. De Jong MD, Boucher CAB, Galasso GJ, Hirsch MS, Kern ER, Lange JMA, Richman DD Consensus symposium on combination therapy. Antiviral Research 1995, 29:5-29.
26. De Man RA, Bartholomeusz A, Niesters HGM, Zondervan PE, Locarnini S The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B virus: Hepatitis B Immune Globulin Escape, Famciclovir Non-Response, followed by lamivudine resistance resulting in graft loss. Journal of Hepatology 1998, 29:669-675.
27. Dienstag J, Perrillo R, Schiff E, Bartholomew M, Vicary C, Rubin M A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995, 333:1657-1661.
28. Dienstag J, Schiff E, Mitchell M, Gitlin N, Lissoos T, Condreay L, Garrett L, Rubin M, Brown N Extended lamivudine retreatment for chronic hepatitis B. Hepatology 1996, 26:A245.
29. Fischer K, Cheng Y-C, Tyrrell D The mutation in duck hepatitis B polymerase which confers resistance to lamivudine (?-L-(-)-thiacytidine, 3TC) also confers cross-resistance to ?-L-dideoxy-5-fluorocytidine. Hepatology 1996, 24:A246.
30. Fu L, Cheng YC Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol 1998, 55:1567-1572.
31. Furman P, Painter G The role of absolute configuration in the anti-HIV and anti-HBV activity of nucleoside analogues. International Antiviral News 1995, 3:74-77.
32. Gilson R, Chopra K, Murray-Lyon I, Newell A, Nelson M, Tedder R, Toole J, Jaffe H, Hellmann N, Weller I A placebo-controlled phase I/II study of Adefovir Dipivoxil (bis-POM PMEA) in patients with chronic hepatitis B infection. Hepatology 1996, 24:281A.
33. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284:825-829.
34. Gunther S, Fischer L, Pult I, Sterneck M, Will H Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999, 52:25-137.
35. Gunther S, Sommer G, Pilkat U, Iwanska A, Wain-Hobson S, Will H, Meyerhans A Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G to A hypermutation. Virology 1997, 235:104-108.
36. Heathcote EJ, Jeffers L, Wright T, Sherman M, Perrillo R, Sacks S, Carithers R, Rustgi V, Di Bisceglie A, Balan V Loss of serum HBV DNA and HBeAg seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled Phase II studies. Hepatology 1998, 28:A620.
37. Heijtink R, De Wilde G, Kruining J, Berk L, Balzarini J, De Clercq E, Holy A, Schalm S Inhibitory effect of 9-(2-phosphonoyl-methoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 1993, 21:141-153.
38. Heijtink R, Kruining J, de Wilde G, Balzarini J, de Clercq E, Schalm S Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother 1994, 38:2180-2182.
39. Hoetelmans RM Sanctuary sites in HIV-1 infection. Antivir Ther 1998, 3:13-17.
40. Hollinger F Hepatitis B Virus. Fields Virology 1996, Lippincott-Raven Publishers, Philadelphia. 3rd Edition.
41. Hsu M, Inouye P, Rezende L, Richard N, Li Z, Prasad VR, Wainberg MA Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res 1997, 25:4532-4536.
42. Huang H, Chopra R, Verdine GL, Harrison SC Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998, 282:1669-1675.
43. Jacobo-Molina A, Ding J, Clark AD, Lu X, Tantillo C, Williams RL, Kamer G, Ferria AL, Clark P Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc National Acad of Sci, USA 1993, 90:6320-6324.
44. Ka-Kit G, Lau K, Tsiang M, Hou J, Yuen S, Carman WF, Zhang L, Gibbs CS, Lam S Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected chinese patients: A viral dynamics study. Hepatology 2000, 32:394-399.
45. Ladner SK, Miller TJ, King RW The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob Agents Chemother 1998, 42:2128-2131.
46. Lai C, Chien R, Leung N, Chang T, Guan R, Tai D, Ng K, Wu P, Dent J, Barber J A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998, 339:61-68.
47. Larder BA, Kemp SD, Harrigan PR Potential mechanism for sustained antiviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
48. Lau JY, Bain VG, Davies SE, O'Grady JG, Alberti A, Alexander GJ, Williams R High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992, 102:956-962.
49. Lee W Hepatitis B virus infection. N Engl J Med 1997, 337:1733-1745.
50. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannzino F, Weber C Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature America 1999, 6:937-943.
51. Lin TS, Luo MZ, Liu MC, Pai SB, Dutschman GE, Cheng YC Antiviral activity of 2', 3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2', 3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem Pharmacol 1994, 47:171-174.
52. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996, 24:711-713.
53. Locarnini S, Birch C Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV infected patients. Journal of Hepatology 1999, 30:536-550.
54. Locarnini SA, Aye TT, De Man R, Angus PW, McCaughan GW, Bartholomeusz AI The emergence of famciclovir resistant mutants in the hepatitis B virus polymerase during therapy in patients following liver transplantation. Hepatology 1997, 26:368A.
55. Mahoney FJ Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999, 12:351-366.
56. Main J, Brown J, Howells C, Galassini R, Crossey M, Karayiannis P, Georgiou P, Atkinson G, Thomas H A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hep 1996, 3:211-215.
57. Mast EE, Alter MJ, Margolis HS Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999, 17:1730-1733.
58. Najera I, Holguin A, Quinones-Mateu ME, Munoz-Fernandez MA, Najera R, Lopez-Galindez C, Domingo E Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995, 69:23-31.
59. Nanni R, Ding J, Jocobo-Molina A, Hughes S, Arnold E Review of HIV-1 reverse transcriptase three dimensional structure: Implications for drug design. Perspectives Drug Discovery Design 1993, 1:129-150.
60. Naoumov NV, Chokshi S, Smith H, Williams R Emergence and characterisation of lamivudine resistant hepatitis B virus variant. Hepatology 1996, 24:282A.
61. Neuhaus P, Mannus M, Atkinson G Safety and efficacy of famciclovir for the treatment of recurrent hepatitis B infection in liver transplant recipients. Hepatology 1997, 26:A528.
62. Nicoll A, Colledge D, Wang Y, Toole J, Dean J, Angus P, Smallwood R, Locarnini S PMEA, an acyclic phosphonate nucleoside analogue with activity against duck hepatitis B virus in vitro. Hepatology 1996, 24:A375.
63. Niesters HG, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus AD Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998, 177:1382-1385.
64. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996, 93:4398-4402.
65. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B. J Med Virol 1999, 59:270-276.
66. Okamoto H, Imai M, Kametani M, Nakamura T, Mayumi M Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J Exp Med 1987, 57:231-236.
67. Ono-Nita SK, Kato N, Shiratori Y, Lan K-H, Yohida H, Carrilho FJ, Omata M Susceptibility of lamivudineresistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999, 103:1635-1640.
68. Oon CJ, Chen WN, Lim N, Koh S, Lim GK, Leong AL, Tan GS Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir. Antiviral Res 1999, 41:113-118.
69. Orito E, Mizokami M, Ina Y, Moriyama EN, Kameshima N, Yamamoto M, Gojobori T Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. Proc Natl Acad Sci USA 1989, 86:7059-7062.
70. Pai S, Liu S-H, Zhu Y-L, Chieng C Inhibition of hepatitis B virus by a novel L-nucleoside 2'-fluoro-5-methyl?-L-arabinofuranosyl uracil. Antimicrob Agents Chemotherapy 1996, 40:380-386.
71. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
72. Piatek AS, Telenti A, Murray MR, El-Hajj H, Jacobs WR, Kramer FR, Alland D Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 2000, 44:103-110.
73. Pichoud C, Seigneres B, Wang Z, Trepo C, Zoulim F Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 1999, 29:230-237.
74. Poch O, Sauvaget I, Delarue M, Tordo N Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. European Molecular Biology Organisation 1989, 8:3867-3874.
75. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999, 9:1048-1051.
76. Shaw T, Locarnini S Combination Chemotherapy for Hepatitis B Virus: The Final Solution?. Hepatology 2000, 32:430-432.
77. Sterneck M, Gunther S, Gerlach J, Naoumov NV, Santantonio T, Fischer L, Rogiers X, Greten H, Williams R, Will H Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis. J Hepatol 1997, 26:754-764.
78. Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000, 38:702-707.
79. Thibault V, Benhamou Y, Seguret C, Bochet M, Katlama C, Bricaire F, Opolon P, Poynard T, Agut H Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol 1999, 37:3013-3016.
80. Tillmann HL, Trautwein C, Bock T, Boker KWH, Jackel E, Glowienka M, Oldhafer K, Bruns J, Condreay LD, Raab HR Mutational analysis of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occuring under HBIg immunoglobulin after liver transplantation. Hepatology 1999, 30:244-256.
81. Tipples A, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996, 24:714-717.
82. Trepo C, Jezek P, Atkinson G, Boon R Efficacy of famciclovir in chronic hepatitis B: Results of a dose finding study. Hepatology 1996, 24:A188.
83. Tsiang M, Rooney JF, Toole JJ, Gibbs CS Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999, 29:1863-1869.
84. Vet JA, Majithia AR, Marras SA, Tyagi S, Dube S, Poiesz BJ, Kramer FR Multiplex detection of four pathogenic retroviruses using molecular beacons. Proc Natl Acad Sci USA 1999, 96:6394-6399.
85. Wijnholds J, Mol CAAM, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc NY Acad Sci 2000, 97:7476-7481.
86. Witcher J, Boudinot F, Baldwin B, Ascenzi M, Tennant B, Du J, Chu C Pharmacokinetics of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl) uracil in woodchucks. Antimicrob Agents Chemother 1997, 41:2184-2187.
87. Xiong X, Flores C, Gibbs C, Toole I Lack of cross resistance to PMEA for human hepatitis B DNA polymerase which expresses lamivudine resistance codons. Hepatology 1997, 26:A1211.
88. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998, 28:1669-1673.
89. Xiong X, Yang H, Westland C, Zou R, Gibbs C In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 2000, 31:219-224.
90. Yeh CT, Chien RN, Chu CM, Liaw YF Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000, 31:1318-1326.
91. Ying C, De Clercq E, Nicholson W, Furman P, Neyts J Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000, 7:161-165.
92. Yokota T, Konno K, Shigeta S, Holy A, Balzarini J, De Clerq E Inhibitory effects of acyclic nucleoside phosphonate analogues on hepatitis B virus DNA synthesis in HB G11 cells. Antiviral Chem Chemother 1994, 5:57-63.
93. Yokota T, Mochizuki S, Konno K, Mori S, Shigeta S, De Clercq E Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob Agents Chemother 1991, 35:394-397.
94. Yuen M-F, Lai C-L Debates in Hepatitis: How to assess HBV DNA reductions in association with therapy. Viral Hepatitis Reviews 1999, 5.